


Pulse Survey: GLP-1 Drugs

This survey, conducted from October 26, 2023 to October 31, 2023, captures employers' coverage and considerations surrounding GLP-1 drugs, which have historically been prescribed for weight loss or diabetes. It also provides a snapshot of other approaches used by employers that offer health care coverage to address certain chronic health conditions. The data below reflects responses from corporate plan sponsors and professional service providers.

Coverage of GLP-1 Drugs* (n=205)




* Respondents were asked to select up to two responses.

Top Ten Factors Regarding GLP-1 Coverage for Obesity Care* (n=205)




* Respondents were asked to select all that apply.

Health Plan Funding (n=202)




Options Besides GLP-1 Drugs Available for Diabetes and Weight Loss* (n=205)



* Respondents were asked to select all that apply.


The following are results from organizations that offer GLP-1 drugs for weight loss.

Cost-Control Mechanisms in Place for GLP-1 Drugs for Weight Loss* (n=56)



* Respondents were asked to select all that apply.

Representation of GLP-1 Drugs for Weight Loss in Total Annual Claims for 2023 (n=56)



Companies Considering Reducing or Restricting Coverage for Any of the Following as a Result of Offering GLP-1 Drugs for Weight Loss* (n=56)

* Respondents were asked to select all that apply.

